Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS



Date/App# patent app List of recent Cytokine-related patents
07/30/15
20150212090 
 Use of a panel of urinary cytokines to predict response to bcg therapy for bladder cancer patent thumbnailnew patent Use of a panel of urinary cytokines to predict response to bcg therapy for bladder cancer
Methods for predicting cancer recurrence following a bcg immunotherapy are provided. In some aspects, cytokine levels from a patient are measured before and after a bcg therapy and the changes in cytokine levels are used to determine the risk of cancer lapse.
Board Of Regents, The University Of Texas System


07/30/15
20150212088 
 Compositions and methods for detecting and treating colorectal cancer patent thumbnailnew patent Compositions and methods for detecting and treating colorectal cancer
The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using il-22 cytokine signaling and/or downstream targets of il-22 cytokine signaling (e.g., stat3, dot1l, suz12, eed) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through il-22 cytokine signaling..
The Regents Of The University Of Michigan


07/23/15
20150203558 
 Long-acting polypeptides and methods of producing same patent thumbnailLong-acting polypeptides and methods of producing same
A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (ctp) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (ctp) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed..
Opko Biologics Ltd.


07/23/15
20150203556 
 Compositions and methods for modulation of il-20 family cytokine activity patent thumbnailCompositions and methods for modulation of il-20 family cytokine activity
Provided herein are compositions comprising one or more agents that inhibit or reduce the activity of il-20. Optionally, the agents further inhibit or reduce the activity of il-24.
The Uab Research Foundation


07/23/15
20150203551 
 Hmgb1 variants and uses thereof patent thumbnailHmgb1 variants and uses thereof
The present invention relates to hmgb1 variants that maintain hmgb1 wild type chemoattractant function while displaying abolished cytokine and/or chemokine stimulating properties. Such molecules are useful in therapy..
Universitá Degli Studi Di Milano - Bicocca


07/23/15
20150202286 
 Toxicity management for anti-tumor activity of cars patent thumbnailToxicity management for anti-tumor activity of cars
The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified t cell expressing a car wherein the car comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a cd3 zeta signaling domain and monitoring the levels of cytokines in the patient post t cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the car t cell in the patient..
The Children's Hospital Of Philadelphai


07/23/15
20150202178 
 Compositions and methods of use of phorbol esters patent thumbnailCompositions and methods of use of phorbol esters
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

07/16/15
20150198601 
 Methods of diagnosing and prognosing colonic polyps patent thumbnailMethods of diagnosing and prognosing colonic polyps
Methods of diagnosing or prognosing a disease or condition associated with increased or over expression of macrophage inhibitory cytokine-1 (mic-1) are disclosed. The methods typically involve detecting a change in the amount of mic-1 in a test body sample from a subject taken at two or more time points.
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of


07/16/15
20150197808 
 Cytokines as prognostic markers of respiratory-tract infection following major surgery patent thumbnailCytokines as prognostic markers of respiratory-tract infection following major surgery
The invention relates to the use of a certain subset of cytokine markers as prognostic variables of infection status in an individual, and especially as prognostic markers of a patients developing severe infection such as pneumonia, and respiratory tract infection following surgery. The subset of cytokine markers consists of the interleukin cytokines il-2, il-7, il-23, il-27, and il-10, and interferon-γ (infγ) and tissue necrosis factor-α (tnfα).
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe


07/16/15
20150197566 
 Polynucleotides encoding antagonists of il-17a, il-17f, and il-23p19 patent thumbnailPolynucleotides encoding antagonists of il-17a, il-17f, and il-23p19
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a, il-17f, and il-23. Antagonists include antibodies and antibody fragments that bind il-23 and that bind il-17a or il-17f, such as antibodies that are cross-reactive for il-17a and il-17f.
Zymogenetics, Inc.


07/16/15
20150196656 

Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof


Fusion proteins comprising cytokines, particularly insulin-like growth factor-1 (igf-1) and variants thereof, epidermal growth factor (egf), and other ligands to the egf receptor, are provided. The fusion proteins further comprise seq id no:1 or other segments having lysine, glutamic acid, or aspartic acid residues.

07/16/15
20150196602 

Stem cell therapy for crohn's disease and ulcerative colitis


A therapeutic process for treating an inflammatory bowel disease (ibd) using mesenchymal stem cells includes the steps of isolating a plurality of human mesenchymal stem cells from a human patient, introducing the plurality of human mesenchymal stem cells into the human patient, reducing human pro-inflammatory cytokines, wherein the human pro-inflammatory cytokines include il-12 and il-18, and increasing human anti-inflammatory cytokines, wherein the human anti-inflammatory cytokines include il-10 and tgf-beta. The human mesenchymal stem cells are isolated from an umbilical cord blood or from a human adipose tissue.

07/16/15
20150196598 

Human cd8+ regulatory t cells inhibit gvhd and preserve general immunity in humanized mice


Graft-versus-host disease (gvhd) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control gvhd may cause general immune suppression and limit the effectiveness of allograft transplantation.
The University Of Hong Kong


07/09/15
20150191522 

Compositions for preserving insulin-producing cells and insulin production and treating diabetes


Nuclear transport modifiers such as csn50 and csn50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (nod) mice, a widely used model of type 1 diabetes (t1d), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. Csn50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of t and b lymphocytes derived from nod mice.
Vanderbilt University


07/02/15
20150185229 

Biomarker of renal dysfunction


The present invention relates to a method for determining predisposition of a subject to developing renal dysfunction induced by physical trauma, hypotension, sepsis and/or septic shock syndrome, wherein the method comprises the steps of:—a. Determining the level of an anti-inflammatory cytokine present in a sample taken from the subject prior to physical trauma, prior to a hypotensive event, prior to sepsis, and/or prior to septic shock syndrome; b.
Belfast Health And Social Care Trust


07/02/15
20150183881 

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins


The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance.
The Johns Hopkins University


07/02/15
20150182487 

Composition for preventing and treating inflammatory diseases and immune diseases, containing apo-9`-fucoxanthinone as active ingredient


The present invention relates to a composition for preventing and treating inflammatory diseases and immune diseases, containing a sargassum muticum extract and apo-9′-fucoxanthinone as active ingredients. According to the present invention, the sargassum muticum extract and apo-9′-fucoxanthinone show an excellent inhibiting activity for the generation of il-12, il-6 and tnf-α, which are inflammatory cytokines, in a macrophage and a dendritic cell due to a stimulating factor causing an inflammatory response, remarkably inhibit mapk and ap-1 activity, and inhibit the activity of nlrp3 inflammasome which is known to be involved in the pathogenesis of various immune inflammatory diseases, and thus can be ultimately useful for the development of an agent for treating inflammatory diseases and immune diseases caused by an excessive immune inflammatory response.
Jeju National University Industry Academic Cooperation Foundation


06/25/15
20150175961 

System and method to facilitate the growth of stem cells


A method and system to maintain adult or embryonic stem cells employing 3-d culture conditions is disclosed. Hydrogel scaffolds, composed of hydrophilic polymer networks are provided to emulate a fully hydrated native extracellular matrix and natural soft tissue.
Oakland University


06/25/15
20150175692 

Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders


The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine il-17a. The disclosure more specifically relates to specific antibodies and proteins that are il-17a antagonists (inhibit the activities of il-17a and il-17af) and are capable of inhibiting il-17a induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo.
Novartis Ag


06/18/15
20150166951 

Novel cell-derived composition


The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed amnion-derived cellular cytokine solution-b (accs-b).
Stemnion, Inc.


06/18/15
20150166678 

Compositions and methods comprising binding proteins for adalimumab


Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine tnf-α and was developed to treat tnf-α mediated inflammatory diseases.
Abbvie Biotechnology Ltd


06/18/15
20150166649 

Compounds and methods for treating inflammatory diseases


A monoclonal secretory iga antibody, which binds to and neutralizes a human proinflammatory cytokine or which binds to and blocks a human proinflammatory cytokine receptor. The secretory iga antibody is useful in treating a variety of inflammatory diseases in humans..
Synthon Biopharmaceuticals B.v.


06/18/15
20150164993 

Pharmaceutical composition having preventative or treatment effect on inflammatory bowel diseases


The present invention relates to a pharmaceutical composition, which contains a mixture of extracts of stemonae radix, asparagi tuber, scutellariae radix, schisandrae fructus, rehmanniae radix preparata, armeniacae semen, and moutan cortex radicis, for suppressing the occurrence of inflammatory bowel diseases due to cigarette smoke, a method for preventing or treating inflammatory bowel diseases, a method for suppressing the expression of inflammatory cytokines by using the composition, and to a food composition, which contains a mixture of extracts of stemonae radix, asparagi tuber, scutellariae radix, schisandrae fructus, rehmanniae radix preparata, armeniacae semen, and moutan cortex radicis, for preventing or ameliorating inflammatory bowel diseases due to cigarette smoke. The pharmaceutical composition, according to the present invention, contains the mixture of extracts of stemonae radix, asparagi tuber, scutellariae radix, schisandrae fructus, rehmanniae radix preparata, armeniacae semen, and moutan cortex radicis, thereby reducing the level of mmp12 expression that is known to destroy il-1β, tnf-α, il-6 and mcp-1, which are inflammatory cytokines that accompany the inflammatory bowel diseases, elastin, and collagen, and thus can be widely used in developing a safe and effective inflammatory bowel disease treating agent..
University-industry Cooperation Group Of Kyung Hee University


06/18/15
20150164583 

Methods and pulsed electric field neuromodulation via an intra-to-extravascular approach


Methods and apparatus are provided for pulsed electric field neuromodulation via an intra-to-extravascular approach, e.g., to effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, changes in cytokine upregulation and other conditions in target neural fibers. In some embodiments, the itev pef system comprises an intravascular catheter having one or more electrodes configured for intra-to-extravascular placement across a wall of patient's vessel into proximity with target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


06/11/15
20150159136 

Methods for inducing migration by dendritic cells and an immune response


Compositions and methods of activating dendritic cells with lmp1 and lmp1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. Lmp1 or lmp1-cd40 chimeric protein may be used to activate and mature dendritic cells.
University Of Miami


06/11/15
20150157710 

Dual ox40 agonist/il-2 cancer therapy methods


Ox40 is a potent immune stimulating target. Provided herein is a method of treating cancer, which includes administering to a subject in need of treatment an ox40 agonist and a common gamma chain (yc) cytokine or an active fragment, variant, analog, or derivative thereof.
Providence Health & Services-oregon D/b/a Providence Portland Medical Center


06/11/15
20150157688 

Composition and affecting cytokines and nf-kb


The present invention discloses a composition and method for effecting various cytokines and nf-κb by administering an effective amount of a phyto-percolate composition to an individual. In various exemplary embodiments, the composition is claimed to be useful for the effective treatment of inflammation, cancer, and/or various infections including hiv by regulation of various interleukins, such as il-10 and il-2, and of transcription factors including nf-κb..
Zivo Bioscience, Inc.


06/11/15
20150157398 

Methods for treating heart arrhythmia


Methods and apparatus are provided for treatment of heart arrhythmia via renal neuromodulation. Such neuromodulation may effectuate irreversible electroporation or electrofusion, ablation, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


06/04/15
20150152387 

Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells


The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated jurkat cells and irradiated epstein-barr virus transformed lymphocyte continuous line (ebv-lcl) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells..
Korea University Research And Business Foundation


06/04/15
20150152383 

Methods for reducing and/or preventing excessive cellular apoptosis


The invention is directed to novel methods for reducing the number of apoptotic cell deaths in a population of cells undergoing excessive cellular apoptosis. The invention is also directed to novel methods for preventing apoptotic cell death in a population of cells at risk for developing excessive cellular apoptosis.
Stemnion, Inc.


06/04/15
20150152188 

An il-15 and il-15r\alpha sushi domain based immunocytokines


The immunocytokine includes (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to the conjugate, wherein the conjugate includes (i) a polypeptide including the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide including the amino acid sequence.. .
Inserm


06/04/15
20150152186 

Site-specific antibody-mediated activation of proapoptotic cytokines: amaize (antibody-mediated apoptosis inducing cytokines)


Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule.
Biontech Ag


06/04/15
20150152156 

Tissue protective peptides and uses thereof


The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
Araim Pharmaceuticals, Inc.


06/04/15
20150152155 

Long-acting polypeptides and methods of producing same


A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (ctp) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (ctp) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed..
Opko Biologics Ltd.


06/04/15
20150152141 

Cytokine


A novel cytokine, u83a, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and hiv/aids, are described..
London School Of Hygiene And Tropical Medicine


06/04/15
20150152138 

Uses of kappa opioid synthetic peptide amides


The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.


06/04/15
20150150944 

Vault complexes for cytokine delivery


The invention relates to compositions of vault complexes containing recombinant cytokine fusion proteins that include a cytokine and a vault targeting domain, and methods of using the vault complexes to deliver the cytokines to a cell or subject, and methods for using the compositions to treat cancer, such as lung cancer.. .
The United States Government Represented By The Department Of Veterans Affairs


06/04/15
20150150935 

Peripheral kappa receptor agonists for reducing pain and inflammation


A method of treating of a mammalian subject suffering from an inflammatory disease or condition by administering a peripherally-restricted kappa opioid receptor agonist for reducing the inflammation is provided. The peripherally-restricted kappa opioid receptor agonist can include a peptide and the peptide can include d-amino acids.
Cara Therapeutics, Inc.


06/04/15
20150150934 

Pharmaceutical composition having preventative or treatment effect on inflammatory bowel diseases comprising stemonae radix extract


The present invention relates to a pharmaceutical composition, which comprises a stemonae radix extract, for preventing or treating the occurrence of inflammatory bowel diseases due to cigarette smoke, a method for preventing or treating the occurrence of inflammatory bowel diseases using the composition, a method for suppressing the expression of inflammatory cytokines using the composition, and to a food composition, which comprises the stemonae radix extract, for preventing or treating the occurrence of inflammatory bowel diseases due to cigarette smoke. The pharmaceutical composition comprising the stemonae radix extract, according to the present invention, reduces the level of mmp12 expression that is known to destroy il-1β, tnf-α, and il-6, which are inflammatory cytokines that accompany the inflammatory bowel diseases, and elastin and collagen, and can suppress decrease in the number of lactobacilli in the intestine, and thus can be widely used in developing a safe and effective inflammatory bowel diseases treating agent..
University-industry Cooperation Group Of Kyung Hee University


06/04/15
20150150915 

Methods for treating ocular contusion and blunt injury and traumatic injury to the optic nerve


The invention is directed to methods for treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve. The invention is further directed to treating ocular contusion and blunt injury to the eye and for treating traumatic injury of the optic nerve by administering to a subject suffering from such conditions amnion-derived cellular cytokine solution (accs), including novel immediate-release, targeted-release, and sustained-release (sr) accs compositions (referred to herein as “sr-accs” compositions) and/or and amnion-derived multipotent progenitor (amp) cell compositions.
Stemnion, Inc.


06/04/15
20150150681 

Tissue repair devices and scaffolds


The present invention relates to multiphasic, three-dimensionally printed, tissue repair devices or scaffolds useful for promoting bone growth and treating bone fracture, defect or deficiency, methods for making the same and methods for promoting bone growth and treating bone fracture, defect or deficiency using the same. The scaffold has a porous bone ingrowth area containing interconnected struts surrounded by a microporous shell.

05/28/15
20150147325 

Serpin fusion polypeptides and methods of use thereof


This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an fc polypeptide or an amino acid sequence that is derived from an fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a wap domain containing polypeptide or a sequence derived from a wap containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules..
Inhibrx Llc


05/28/15
20150147324 

Wap domain fusion polypeptides and methods of use thereof


This invention relates to fusion proteins that include a whey acidic protein (wap) domain-containing polypeptide and a second polypeptide. Additionally, the invention relates to fusion proteins that include a wap domain-containing polypeptide a second polypeptide, and a third polypeptide.
Inhibrx Llc


05/21/15
20150141332 

Methods for diagnosing osteoarthritis


Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor ab (pdgf-ab), platelet-derived growth factor bb (pdgf-bb), and epidermal growth factor (egf). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid.
Biomet Biologics, Llc


05/21/15
20150140112 

Composition comprising extract of mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis


The present invention relates to a composition comprising an extract of a mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis, wherein the composition has the excellent effect of treating atopic dermatitis through the synergistic interaction of the anti-inflammatory effect of undaria pinnatifida sporophylls and the cell regenerative effect of ascidian shells. The composition of the invention is not involved in the suppression of cytokine production.
Industry-academic Cooperation Foundation Gyeongsang National University


05/21/15
20150139951 

Engineered antibody-interferon mutant fusion molecules


The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to fusion molecule constructs wherein a tumor associated antigen (taa) antibody (ab) serves as a targeting moiety to selectively deliver a cytokine to a tumor cell for purposes of killing or inhibiting the growth or proliferation of said tumor cell.
Immungene Inc.


05/21/15
20150136693 

Cytokine adsorption sheet, manufacturing the same, and blood filter comprising the same


A cytokine adsorption sheet comprises a nanofiber web formed by electrospinning a spinning solution prepared by mixing an adsorbent material capable of adsorbing cytokine and an electrospinnable polymer material. Thus, the dissolution of the adsorbent material by blood can be prevented..
Snu R&db Foundation


05/14/15
20150132443 

Purification program


A method for a mammal to remove toxins from the mammal's system, the method includes the steps of providing instructions for the mammal to ingest a set of substances periodically according to a set of instructions and to practice a set of wellness regimen periodically. The set of instructions comprises instructing the mammal to periodically ingest a predetermined amount of a rejuvenating substances providing the mammal with support of antioxidant activity, cytokine balance, detoxification, gastrointestinal and liver health; a predetermined amount of soluble dietary fiber substances; a predetermined amount of grasses; a predetermined amount of an antioxidant substances providing the mammal with support of antioxidant activities; predetermined amount of omega fatty acid substances and a predetermined amount of green tea.

05/14/15
20150132343 

System and the detection and treatment of infection by a microbial agent associated with hiv infection


A method of treating a patient, comprising administering at least one antibiotic, e.g., doxycycline and ciprofloxacin, sufficient to substantially treat an intracellular bacterial organism present in at least erythrocytes, e.g., over a course of at least two weeks; and subsequently administering at least one immunostimulant, e.g., which directly or indirectly increases levels of immunostimulatory cytokines in the patient, and at least one antioxidant, e.g., glutathione, to effectively treat a coinfection of the patient with a virus. The intracellular bacterial organism may be a rickettsiales-like organism, and the virus may be hiv..

05/14/15
20150132287 

Methods of decreasing leptin levels or activity for treating inflammation


The present invention is directed to methods for modulating the th/th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the expression, or the activity of leptin in a subject sufficient to modulate the th1/th2 cell balance toward anti-inflammatory cytokine producing cells. The invention is also directed to methods of treatment of an immune-related disorder in a subject comprising decreasing the amount, the expression, or the activity of leptin in the subject sufficient to treat the immune-related disorder..

05/07/15
20150127105 

Method of treating scoliosis using a biological implant


The present invention is a bone growth stimulating and promoting cytokine type biological implant preferably comprising pth coated with a controlled release biodegradable coating that is implanted preferably in the concave side of a scoliotically curved spine in combination with a bone growth inhibiting type biological implant preferably comprising methotrexate or like anti-metabolite coated with a controlled release biodegradable coating that is implanted preferably in the convex side of a scoliotically curved spine. The insertion of the biological implant is highly non-invasion, especially as compared to more conventional spine surgical methods, and the biological implant does not decrease spinal mobility or spinal range of motion..

05/07/15
20150126709 

Trail collectin fusion proteins


The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.
Apogenix Gmbh


05/07/15
20150126480 

Biomarker of renal dysfunction


The present invention relates to a method for a method for predicting the development of renal dysfunction in a subject following physical trauma, hypotension, sepsis and/or septic shock syndrome, wherein the method comprises the steps of: —a. Determining the level of an anti-inflammatory cytokine present in a sample taken from the subject after physical trauma, after a hypotensive event, after sepsis, and/or after septic shock syndrome; b.
Belfast Health And Social Care Trust


05/07/15
20150125421 

Cytokine-based fusion proteins for treatment of immune disorders


The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided..
East Carolina University


05/07/15
20150125419 

Trail single chain molecules


The present invention refers to single-chain fusion proteins comprising three soluble tnf superfamily (tnfsf) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications..
Apogenix Gmbh


04/30/15
20150119409 

Compositions and methods for the treatment of inflammatory disorders


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

04/23/15
20150111823 

Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue


The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hghrelin.. .
Ipsen Pharma S.a.s.


04/23/15
20150110790 

Composition for modulating the expression of cell adhesion molecules


A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment..
Cda Royalty Investors, Llc


04/23/15
20150110753 

Biomatrix scaffolds


The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same.. .
The University Of North Carolina At Chapel Hill


04/23/15
20150110734 

Trail single chain molecules


The present invention refers to single-chain fusion proteins comprising three soluble tnf superfamily (tnfsf) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications..
Apogenix Gmbh


04/16/15
20150105400 

Therapeutic agent for cerebral infarction


The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as tnf-β, il-1β, il-6 and mcp-1 and the like..
Mitsubishi Tanabe Pharma Corporation


04/16/15
20150104483 

Therapeutic agent for cerebral infarction


The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as tnf-α, il-1β, il-6 and mcp-1 and the like..
Mitsubishi Tanabe Pharma Corporation


04/16/15
20150104414 

Cytokines and neuroantigens for treatment of immune disorders


The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided..
East Carolina University


04/16/15
20150104410 

Serpin fusion polypeptides and methods of use thereof


This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an fc polypeptide or an amino acid sequence that is derived from an fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a wap domain containing polypeptide or a sequence derived from a wap containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules..
Inhibrx Biopharma Llc


04/16/15
20150103591 

Semiconductor memory with integrated biologic element


A memory includes cytokines, such as macromolecule proteins, as a poly-state data storage. Each fold state of multiple fold states of a protein are associated with a data value.
Toshiba America Electronic Components, Inc.


04/09/15
20150100100 

Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation


A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist.

04/09/15
20150099652 

In vitro process for the quick determination of a patient's status relating to infection with mycobacterium tuberculosis


An in-vitro process for the quick determination of the infection status of a mycobacterium tuberculosis infection from whole blood in terms of active or latent tuberculosis, comprising the steps of: stimulating an antigen-specific t cell that is present in a first sample of whole blood with purified protein derivative (ppd) in the presence of antibodies against cd28, or cd28 and cd49d; processing of ppd by antigen-presenting coils (apc) by incubating for 1.5 h to 2.5 h, especially for 2 h, at 35° c. To 39° c., especially at 37° c., optionally with raiding c02; then adding a secretion inhibitor; effecting an intensive mixing; and another incubation for a period of at least 2.5 h at a temperature of from 35° c.
Red Flag Diagnostics Gmbh


04/02/15
20150094285 

Phytochemical compositions including sesamin for anti-inflammatory, anti-cytokine storm, and other uses


A composition (e.g., phytochemical composition) including sesamin, the composition exhibiting anti-inflammatory, anti-cytokine storm, connective tissue preservation, anti-viral, and/or other properties in biological tissue. The phytochemical composition therapeutically affects a pro-inflammatory cytokine condition, for instance facilitating or effectuating decrease in a quantity of a pro-inflammatory cytokine, for example, interleukin-1 and tumor necrosis-alpha.
Chiang Mai University


04/02/15
20150093463 

Nutritional composition containing a peptide component with anti-inflammatory properties and uses thereof


The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising seq id no 4, seq id no 13, seq id no 17, seq id no 21, seq id no 24, seq id no 30, seq id no 31, seq id no 32, seq id no 51, seq id no 57, seq id no 60, and seq id no 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e.
Mead Johnson Nutrition Company




Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.2764

4472

1 - 1 - 101